Prediction of Acute Kidney Injury in Patients With COVID-19
Keywords
Abstract
Description
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is rapidly spreading around the world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019 (COVID-19). Two other coronavirus infections, SARS in 2002-2003 and Middle East Respiratory Syndrome (MERS) in 2012, both caused severe respiratory syndrome in humans. All 3 of these emerging infectious diseases are caused by β-coronaviruses.
Although COVID-19 primarily affects the lungs and may cause severe hypoxemia, other organs including the GI tract, heart and kidney are affected. Acute kidney injury secondary to COVID-19 (COV-AKI) is reported to occur in about 15-25% of patients hospitalized with COVID-19 infection. The majority of AKI cases are mild to moderate with renal replacement requirement in about 25%. However, AKI was much more common in non-survivors (>50%). Although kidney failure appears to occur late in the course, patients may begin to develop AKI within the first 3 days of hospitalization. Similar to AKI in other settings,3 COV-AKI is likely to be of variable etiology. Thus, there may be a long window for treatment.
The two cell-cycle arrest markers, tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth-factor binding protein 7 (IGFBP7), have been shown to early predict the occurrence of AKI in cardiac surgical and critically ill patients. However, there is no data available whether (TIMP-2)*(IGFBP7) can predict the occurrence of AKI in the COVID19 setting. Early prediction of AKI may be valuable to optimize therapeutic management in order to improve patient's outcome and might be helpful to triage patients.
The goal of this observational trial is to evaluate whether (TIMP-2)*(IGFBP7) early predicts the occurrence of AKI in critically ill patients with SARS-CoV2 associated ARDS.
Dates
| Last Verified: | 04/30/2020 |
| First Submitted: | 05/17/2020 |
| Estimated Enrollment Submitted: | 05/26/2020 |
| First Posted: | 05/27/2020 |
| Last Update Submitted: | 05/26/2020 |
| Last Update Posted: | 05/27/2020 |
| Actual Study Start Date: | 05/24/2020 |
| Estimated Primary Completion Date: | 01/31/2021 |
| Estimated Study Completion Date: | 02/28/2021 |
Condition or disease
Phase
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Sampling method | Probability Sample |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: 1. Moderate or severe ARDS according to the Berlin definition 2. SARS-CoV2 positive test 3. Age ≥ 18 years 4. Informed consent Exclusion Criteria: 1. Pre-existing AKI 2. Severe CKD with eGFR<20ml/min 3. Chronic dialysis dependency 4. Kidney transplant within the last 12 months 5. Pregnancy, breastfeeding 6. Persons with any kind of dependency on the investigator or employed by the sponsor or investigator. |
Outcome
Primary Outcome Measures
1. Occurence of acute kidney injury (AKI) [within 7 days after beginning of moderate or severe ARDS]
Secondary Outcome Measures
1. Occurence of transient and persistent AKI [within 7 days after beginning of moderate or severe ARDS]
2. Occurence of Renal replacement therapy during hospital stay [up to 4 weeks after beginning of moderate or severe ARDS]
3. Duration of renal replacement therapy [up to 4 weeks after beginning of moderate or severe ARDS]
4. Mortality [up to 4 weeks after beginning of moderate or severe ARDS]
5. Duration of mechanical ventilation [up to 4 weeks after beginning of moderate or severe ARDS]
6. Duration of vasopressor administration [up to 4 weeks after beginning of moderate or severe ARDS]
7. ICU length of stay [up to 4 weeks after beginning of moderate or severe ARDS]
8. Hospital length of stay [up to 4 weeks after beginning of moderate or severe ARDS]
Other Outcome Measures
1. Add-on analysis: pro- and antiinflammatory mediators [within 7 days after beginning of moderate or severe ARDS]
